Loading
NT
Novelion Therapeutics Inc. Stock: price and insider trades · Canada
No insider purchase over the last 90 days. The latest, by STONEPINE CAPITAL, L.P., was filed 12 Dec 2019.
Novelion Therapeutics Inc.: what insiders have been doing
Novelion Therapeutics Inc. is a listed company. Its directors and officers file their transactions with SEDI. The past year has been quiet: not a single insider filing for Novelion Therapeutics Inc. The previous disclosure was published on 13 December 2019.
Our records for Novelion Therapeutics Inc. go back to 2016, with 38 purchases and 20 sales on the open market in total.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
165
Thresholds
n/a
Buy Volume
€1M
38 ops. · all time
Sell Volume
€512,700
20 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 13 December 2019
Declarations165 total
5,202 shares@ CA$0.69162.6% of flowCommon SharesTSXSEDI:3465133
Canonical exit: 9 Mar 2020 (T+90)
40 shares@ CA$0.690.0% of flowCommon SharesTSXSEDI:3465134
Canonical exit: 10 Mar 2020 (T+90)
1,000 shares@ CA$0.700.5% of flowCommon SharesTSXSEDI:3465135
Canonical exit: 11 Mar 2020 (T+90)
5,202 shares@ US$0.69162.5% of flowCommon StockSEC:0001567619-19-022982:0
Canonical exit: 9 Mar 2020 (T+90)
40 shares@ US$0.690.0% of flowCommon StockSEC:0001567619-19-022982:1
Canonical exit: 10 Mar 2020 (T+90)
1,000 shares@ US$0.700.5% of flowCommon StockSEC:0001567619-19-022982:2
Canonical exit: 11 Mar 2020 (T+90)
5,160 shares@ US$0.702.5% of flowCommon StockSEC:0001567619-19-022780:0
Canonical exit: 4 Mar 2020 (T+90)
40 shares@ US$0.700.0% of flowCommon StockSEC:0001567619-19-022780:1
Canonical exit: 5 Mar 2020 (T+90)
4,500 shares@ US$0.702.2% of flowCommon StockSEC:0001567619-19-022780:2
Canonical exit: 8 Mar 2020 (T+90)
89,845 shares@ US$0.746146.8% of flowCommon StockSEC:0001567619-19-022304:0
Canonical exit: 20 Feb 2020 (T+90)
89,845 shares@ CA$0.746149.1% of flowCommon SharesTSXSEDI:3455551
Canonical exit: 20 Feb 2020 (T+90)
100,000 shares@ US$0.64945.5% of flowCommon StockSEC:0001567619-19-019667:0
Canonical exit: 9 Jan 2020 (T+90)
100,000 shares@ CA$0.64947.7% of flowCommon SharesTSXSEDI:3439463
Canonical exit: 9 Jan 2020 (T+90)
Common SharesTSXSEDI:3439462
5,733 shares@ CA$0.7677.3% of flowCommon SharesTSXSEDI:3429814
1,688 shares@ CA$0.7622.7% of flowCommon SharesTSXSEDI:3429828
3,926 shares@ CA$0.7614.3% of flowCommon SharesTSXSEDI:3429802
13,333 shares@ CA$0.7648.7% of flowCommon SharesTSXSEDI:3429808
1,688 shares@ US$0.7619.4% of flowCommon SharesSEC:0001104659-19-051595:0
3,926 shares@ US$0.7663.0% of flowCommon StockSEC:0001104659-19-051596:0
273 shares@ CA$1.2220.2% of flowCommon SharesTSXSEDI:3367002
212 shares@ CA$1.223.0% of flowCommon SharesTSXSEDI:3366991
155 shares@ CA$1.226.1% of flowCommon SharesTSXSEDI:3366998
546 shares@ CA$1.2221.6% of flowCommon SharesTSXSEDI:3366995
722 shares@ CA$1.2210.1% of flowCommon SharesTSXSEDI:3366989
25 of 165 declarations
About Novelion Therapeutics Inc.
Novelion Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.
